✦ LIBER ✦

Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia

✍ Scribed by Willem J. van Heeckeren; Pingfu Fu; Paul M. Barr; Lisa M. Arfons; Mark H. Kirschbaum; Hillard M. Lazarus; Brenda W. Cooper

Book ID: 116648405
Publisher: Elsevier
Year: 2011
Tongue: English
Weight: 342 KB
Volume: 2
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2011.02.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of sodium salicylate in pa

Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

✍ Virginia M. Klimek; Emily K. Dolezal; Larry Smith; Gerald Soff; Stephen D. Nimer 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 198 KB

162. Phase II clinical trial with hexame

162. Phase II clinical trial with hexamethylene bisacetamide (HMBA) in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)

✍ Michaeli, J; Andreeff, M; Stone, R; Young, CL; Kufe, D; Rifkind, RA; Marks, Pa 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Phase I/II multicenter study to assess t

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

✍ H. M. Kantarjian, S. Padmanabhan, W. Stock, M. S. Tallman, G. A. Curt, J. Li, A. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 188 KB

A Phase I–II trial of escalating doses o

A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

✍ Charles A. Koller; Hagop M. Kantarjian; Eric J. Feldman; Susan O'Brien; Mary Bet 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia. Nevertheless, there is considerable room for improvement in the treatment

Safety, tolerability and immunogenicity

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

✍ N. Groth; E. Montomoli; C. Gentile; I. Manini; R. Bugarini; A. Podda 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Imatinib in combination with cytarabine

Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials

✍ François Guilhot; Martine Gardembas; Philippe Rousselot; Michel Tulliez; Magda V 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB